RheumaGen Australia
RheumaGen Australia is a private cell and gene therapy company engineering a new class of therapeutics to cure major autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies.
RheumaGen Australia is responsible for advancing the HLA gene-edited cell therapy for refractory rheumatoid arthritis to a Phase I clinical trial in Australia and for commercialising HLA gene-edited cell therapies for rheumatoid arthritis in Australia.
Our Vision
Our vision is to one day help relieve the burden on the hundreds of thousands of Australians suffering from rheumatoid arthritis.
Board of Directors
Bruce Goodwin, MBA
Bruce Goodwin has over four decades of experience in the life sciences sector and currently serves on the boards of six healthcare organisations. Bruce previously served as Managing Director, Australia, and Company President, Japan, for the Janssen Pharmaceutical Companies of Johnson & Johnson. He has substantial experience at the board level of industry bodies in both countries.
Shanny Dyer, Ph.D.
Dr. Shanny Dyer is a seasoned director and senior executive with a drug-development background across industry, government, and academia. Dr. Dyer previously led the Association of Regulatory and Clinical Scientists (ARCS), representing professionals commercialising innovation in Australia. She has held numerous board positions in startups and mid-sized technology businesses as well as senior executive roles in universities and at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia’s premier national research organisation.
Ryan Hart, J.D.
Ryan is the Chief Legal Officer of RheumaGen, Inc. He is a former Assistant United States Attorney and corporate litigator. He earned his law degree from Georgetown Law School in Washington, DC.
Advisors
Prof. Georg Schett, M.D.
Dr. Schett is an internationally recognized expert in rheumatic and autoimmune diseases, currently serving as Vice President of Research Friedrich-Alexander Universitat Erlangen-Nürnberg, Germany. Dr. Schett’s pioneering work with CAR T-cell therapy in refractory systemic lupus paved the way for a whole new field of autoimmune patient care.
Brian Freed, Ph.D.
Dr. Freed is the Chief Science Officer and Co-Founder of RheumaGen. He is also the Executive Director of ClinImmune Cell & Gene Therapy, Professor of Medicine and Immunology at the University of Colorado School of Medicine, and the inventor of RheumaGen’s breakthrough HLA gene editing technology. Dr. Freed is a world class expert in the HLA gene, with greater than 40 years of experience and more than 100 publications in the areas of immunogenetics, biotherapeutics, histocompatibility, transplantation, and stem cell banking.
B Robert Mozayeni, M.D.
Dr. B. Robert Mozayeni is an internist, rheumatologist, and medical scientist. He is also an expert in translational medicine – advancing medical science safely and efficiently into medical practice. Dr. Mozayeni has practiced medicine for more than 30 years, specializing in the evaluation and treatment of inflammatory diseases, especially treatment-resistant autoimmune patients. He has special research and clinical expertise on an aspect of inflammation related to persistent infection and its relation to vascular physiology. He is a member of the American College of Physicians and previously, a Fellow of the American College of Rheumatology.